To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
December 21, 2005
William R. Sellers, MD (Damon Runyon Clinical Investigator '01-'05) reported that a new class of drugs called MEK inhibitors selectively suppresses growth of cancer cells and tumors that harbor a mutation in the BRAF gene. BRAF is a protein that acts as a critical regulator of cellular growth, differentiation, and survival.